Premium
Remission induction in a Jehovah's Witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin
Author(s) -
Bareford D.,
Odeh B.,
Narayanan S.,
Wiltshire S.
Publication year - 2005
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/j.1365-3148.2005.00611.x
Subject(s) - gemtuzumab ozogamicin , pancytopenia , medicine , myeloid leukaemia , bone marrow , cd33 , genetics , stem cell , cd34 , biology
summary . A 40‐year‐old patient, who was a Jehovah's Witness, with acute myeloid leukaemia entered remission using a chemotherapeutic based regime aided by the addition of gemtuzumab ozogamicin without requiring any blood product support. The use of gemtuzumab ozogamicin may have helped avoid fatal pancytopenia. The use of gemtuzumab ozogamicin might be considered in similar situations.